Surface Oncology, Inc.
SURFN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
SURF News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
Dry Eye Disease
SURF-201
Post-surgical Ocular Inflammation
0.02% Betamethasone Sodium Phosphate
Dry Eye Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate) | Phase 2 | Dry Eye Disease | - | - |
SURF-201 | Phase 2 | Post-surgical Ocular Inflammation | - | - |
0.02% Betamethasone Sodium Phosphate | Phase 2 | Dry Eye Disease | - | - |
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply